Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study

The Lancet Oncology

Volumn 13, Issue 12, 2012, Pages 1234-1241

  Mamot, Christoph ^a,c   Ritschard, Reto ^a   Wicki, Andreas ^a   Stehle, Gregor ^a   Dieterle, Thomas ^a   Bubendorf, Lukas ^b   Hilker, Christoph ^a   Deuster, Stefanie ^a   Herrmann, Richard ^a   Rochlitz, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DOXORUBICIN; DOXORUBICIN LOADED EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY IMMUNOLIPOSOME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOLIPOSOME; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; BLADDER INFECTION; CANDIDIASIS; CARDIOTOXICITY; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY PALM; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL BLEEDING; PANCREAS CANCER; PHARYNX HEMORRHAGE; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSIS; SENSORY NEUROPATHY; SEPTICEMIA; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; STOMACH PERFORATION; STOMATITIS; SUICIDE ATTEMPT; SWITZERLAND; THORAX PAIN; THROMBOCYTOPENIA; URINE RETENTION; UROGENITAL TRACT TUMOR; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NANOCONJUGATES; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84870243896     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70476-X     Document Type: Article

References (19)

1. Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009, 20:816-827.
2. Lasic DD Doxorubicin in sterically stabilized liposomes. Nature 1996, 380:561-562.
3. Allen TM, Cullis PR Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
4. Noble CO, Kirpotin DB, Hayes ME, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004, 8:335-353.
5. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997, 15:653-659.
6. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
7. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323-3329.
8. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
9. Mendelsohn J Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20(suppl):1S-13S.
10. Bardelli A, Siena S Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
11. Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003, 63:3154-3161.
12. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005, 65:11631-11638.
13. Mamot C, Ritschard R, Wicki A, et al. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J Drug Target 2012, 20:422-432.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
15. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011, 29:398-405.
16. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
17. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
18. Hong RL, Tseng YL Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001, 91:1826-1833.
19. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.